Literature DB >> 22935568

Conditional targeting of tumor necrosis factor receptor-associated factor 6 reveals opposing functions of Toll-like receptor signaling in endothelial and myeloid cells in a mouse model of atherosclerosis.

Apostolos Polykratis1, Geert van Loo, Sofia Xanthoulea, Martin Hellmich, Manolis Pasparakis.   

Abstract

BACKGROUND: Previous studies implicated Toll-like receptor signaling as a critical pathogenic pathway in atherosclerosis, but the cell-specific mechanisms by which Toll-like receptors act to control atherosclerotic plaque development remain poorly understood. METHODS AND
RESULTS: To study the cell-specific role of tumor necrosis factor receptor-associated factor 6 (TRAF6) in atherosclerosis, we generated ApoE(-/-) mice with endothelial cell- or myeloid cell-specific TRAF6 deficiency using Cre/LoxP-mediated gene targeting. Endothelial TRAF6 deficiency reduced atherosclerosis in female ApoE(-/-) mice by inhibiting nuclear factor-κB-dependent proinflammatory gene expression and monocyte adhesion to endothelial cells. In contrast, myeloid cell-specific TRAF6 deficiency caused exacerbated atherosclerosis, with larger plaques containing more necrotic areas in both male and female ApoE(-/-) mice. TRAF6-deficient macrophages showed impaired expression of the antiinflammatory and atheroprotective cytokine interleukin-10, elevated endoplasmic reticulum stress, increased sensitivity to oxidized low-density lipoprotein-induced apoptosis, and reduced capacity to clear apoptotic cells. Thus, the reduced antiinflammatory properties, coupled with increased sensitivity to apoptosis and impaired efferocytosis capacity of TRAF6-deficient macrophages, result in exacerbated atherosclerosis development in TRAF6(MYKO)/ApoE(-/-) mice.
CONCLUSION: Toll-like receptor-mediated TRAF6 signaling acts in endothelial cells to promote atherosclerosis but displays atheroprotective, antiinflammatory and prosurvival functions in myeloid cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22935568     DOI: 10.1161/CIRCULATIONAHA.112.100339

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Novel interaction of antioxidant-1 with TRAF4: role in inflammatory responses in endothelial cells.

Authors:  Archita Das; Varadarajan Sudhahar; Masuko Ushio-Fukai; Tohru Fukai
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-25       Impact factor: 4.249

Review 2.  Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases: at the heart of it all.

Authors:  Muhammad Abdullah; Jessica M Berthiaume; Monte S Willis
Journal:  Transl Res       Date:  2017-11-07       Impact factor: 7.012

3.  Directing TRAF-ic: cell-specific TRAF6 signaling in chronic inflammation and atherosclerosis.

Authors:  Ellen O Weinberg; Caroline Attardo Genco
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

4.  Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach.

Authors:  Zi-Qi Meng; Jia-Rui Wu; Ying-Li Zhu; Wei Zhou; Chang-Geng Fu; Xin-Kui Liu; Shu-Yu Liu; Meng-Wei Ni; Si-Yu Guo
Journal:  Chin J Integr Med       Date:  2020-05-22       Impact factor: 1.978

5.  TRAF3IP2 mediates atherosclerotic plaque development and vulnerability in ApoE(-/-) mice.

Authors:  Siva Sankara Vara Prasad Sakamuri; Yusuke Higashi; Sergiy Sukhanov; Jalahalli M Siddesha; Patrice Delafontaine; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Atherosclerosis       Date:  2016-05-19       Impact factor: 5.162

Review 6.  Endothelial microRNAs and atherosclerosis.

Authors:  Xinghui Sun; Nathan Belkin; Mark W Feinberg
Journal:  Curr Atheroscler Rep       Date:  2013-12       Impact factor: 5.113

7.  USP20 (Ubiquitin-Specific Protease 20) Inhibits TNF (Tumor Necrosis Factor)-Triggered Smooth Muscle Cell Inflammation and Attenuates Atherosclerosis.

Authors:  Pierre-Yves Jean-Charles; Jiao-Hui Wu; Lisheng Zhang; Suneet Kaur; Igor Nepliouev; Jonathan A Stiber; Leigh Brian; Rui Qi; Virginia Wertman; Sudha K Shenoy; Neil J Freedman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

8.  Potential role of Toll-like receptors in programming of vascular dysfunction.

Authors:  Jennifer A Thompson; R Clinton Webb
Journal:  Clin Sci (Lond)       Date:  2013-03-13       Impact factor: 6.124

9.  Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Xinghui Sun; Shaolin He; A K M Wara; Basak Icli; Eugenia Shvartz; Yevgenia Tesmenitsky; Nathan Belkin; Dazhu Li; Timothy S Blackwell; Galina K Sukhova; Kevin Croce; Mark W Feinberg
Journal:  Circ Res       Date:  2013-10-01       Impact factor: 17.367

Review 10.  Anti-inflammatory therapy in chronic disease: challenges and opportunities.

Authors:  Ira Tabas; Christopher K Glass
Journal:  Science       Date:  2013-01-11       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.